Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes | Synapse
March 3, 2026Open Access
Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes
Key Points
Clinical risk scores predict insulin requirements better than fasting beta-cell function markers, highlighting their utility.
Individuals with non-insulin-deficient type 2 diabetes demonstrate a clearer need for clinical risk scores over fasting c-peptide levels.
Observational analysis evaluated clinical characteristics against fasting c-peptide levels in predicting insulin needs.
This approach highlights potential improvements in diabetes management, indicating the need for refined predictive tools.
Abstract
Clinical characteristics outperformed fasting beta-cell function markers in predicting insulin requirements in non-insulin-deficient type 2 diabetes.